Epidemiological.

This year’s symposium will highlight new therapies in the pipeline, new methods with existing brokers and emerging biology which will affect the quest for personalized medicine. To help you plan your protection of the symposium, the scheduled program schedule is available at An electric press kit containing the pr announcements and highlighted abstracts will be accessible to subscribing reporters one week prior to the symposium via EurekAlert! and Newswise, and by demand through the AACR Communications Section. Related StoriesFDA grants accelerated authorization for Tagrisso to treat patients with advanced NSCLCCornell biomedical engineers develop 'very natural killer cells' to destroy malignancy cells in lymph nodesNew RNA check of blood platelets can be used to identify area of cancerThis year’s CTRC-AACR San Antonio Breasts Cancer tumor Symposium will highlight: results of the AZURE trial, which will define the role of zolendronic acid; new data on the effect of obesity on risk and individual management; how clinicians might move beyond Herceptin in controlling HER2 positive breast cancer; the role of circulating tumor cells in patient risk and management; and mammography compliance data in the overall population.The CTRC-AACR San Antonio Breast Cancer Symposium attracts world leaders in cancer treatment and research, including clinical oncologists, fundamental scientists, translational epidemiologists and researchers, attempting to improve prevention, medical diagnosis and patient care with the ultimate goal of eradicating breasts cancer.Under conditions of the merger contract, Eclipsys stockholders will receive 1.2 shares of Allscripts for each share of Eclipsys, a 19 % premium based on the June 8th closing price. By combining the leading physician-office and post-acute treatment solutions from Allscripts with Eclipsys’s leading enterprise solutions for hospitals and health systems, the combined company shall offer a single system of clinical, financial, information and connectivity solutions. The mixed company’s client base includes over 180,000 U.S.